viernes, 24 de septiembre de 2010

FDA restricts rosiglitazone; EMA pulls the plug

September 23, 2010 Sue Hughes, Lisa Nainggolan, Shelley Wood
Silver Springs, MD and London, UK (updated)

The US FDA has decided that rosiglitazone (Avandia, GlaxoSmithKline) can remain available, but only under a very stringent restricted-access program. However, the European Medicines Agency (EMA) has recommended the suspension of the marketing authorizations for all rosiglitazone-containing antidiabetes medications licensed in the EU—Avandia, Avandamet, and Avaglim.


No hay comentarios:

Publicar un comentario